Salute e Benessere

Increasing Tendency of Consumers to Spend on Products that Enhance Youthfulness…

Anti-aging creams and lotions play a significant role in providing a youthful glow and moisturization to the skin. The valuation for the global anti-aging vitamins market was around US$ 1.4 billion in 2022. The market is projected to exhibit a CAGR growth of 8.7% over the forecast period and reach a valuation of US$ 3.5 billion by 2033. Anti-aging creams and lotions play a significant role in providing a youthful glow and moisturization to the skin. The valuation for theglobal anti-aging...

Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep

New Phase 3 strategy provides significant value-creation opportunities New Phase 3 strategy provides significant value-creation opportunities SAN DIEGO, CAandCALGARY, AB,Nov. 9, 2023/PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (Oncolytics) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, provided an update on the planned program for pelareorep in pancreatic ductal adenocarcinoma (PDAC). Oncolytics' collaborator, The Pancreatic Cancer...

Virbac : Declaration of the number of shares and voting rights 10/2023

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsOctober, 31 20238 458 000Gross total of voting rights :...

TREEFROG THERAPEUTICS REINFORCES EXECUTIVE COMMITTEE WITH THREE NEW MEMBERS

"Since our inception in 2018, TreeFrog has made great strides, and I am proud of the progress the teams have made in our therapeutic programs, technology and partnerships. We are part of the revolution in medicine, pioneering therapeutics and technology in cell therapy. Reinforcing the Executive Committee team is crucial for the next phase in our future growth," Frederic Desdouits, PhD, CEO of TreeFrog Therapeutics. "Since our inception in 2018, TreeFrog has made great strides…

Kanazawa University research: Genetic switches in tumor development

The suppressive effect of TGF-ß signaling happens through the stimulation of cell differentiation — the process through which dividing cells acquire their type or function. The malignant progression of cancers, on the other hand, comes from a process called epithelial-mesenchymal transition (EMT), in which an epithelial cell transforms into a mesenchymal cell type. The former is a 'stationary' type of cell, found in epithelial tissue, whereas the latter is a more 'migratory' type of cell found…

Genmab to Present at Jefferies London Healthcare Conference

Media Release COPENHAGEN, Denmark; November 9, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony Pagano will take part in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2023 at 11:00 AM CET / 5:00 AM EST. A webcast of the event will be available on Genmab's website at h ttps://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is...

3D Printing Materials Market worth $10.8 billion by 2033 - Exclusive Report by…

The aerospace and automotive industries are positioned to make a significant impact on the 3D printing materials industry. Both sectors have been at the forefront of adopting 3D printing technology to revolutionize their manufacturing processes. In the aerospace industry, 3D printing is instrumental in producing lightweight, complex components and parts, especially for aircraft and spacecraft. This technology allows for the creation of intricate designs and structures that were previously…

Agenda for Essity's webcast - Innovating for profitable and sustainable growth

"Innovation drives Essity's competitiveness and accelerates growth opportunities. Through our innovation work, we achieve happy customers and consumers, increased sales and profit as well as a leading position in sustainability," says Magnus Groth, President and CEO of Essity. "Innovation drives Essity's competitiveness and accelerates growth opportunities. Through our innovation work, we achieve happy customers and consumers, increased sales and profit as well as a leading…

Immunovia Publishes Interim Report for January-September 2023

Significant events after the period Significant events after the period CEO's comments: During the third quarter we made significant changes to streamline Immunovia and made important progress in developing our next-generation test. As we move forward, we are focused on the rapid execution of our plan to develop and validate the new product. Additionally, we are exploring strategic partnerships that will allow us to succeed in 2024 and beyond. Our transformation is nearly...

Novozymes launches Quara® LowP for renewable diesel feedstock pre-treatment

Novozymes, a global leader in biosolutions, marks a significant milestone in the renewable diesel and SAF (Sustainable Aviation Fuel) industry with the launch of Quara® LowP, an enzymatic solution designed to transform the feedstock pre-treatment process.Copenhagen, Denmark – 9 November, 2023.As the world seeks sustainable alternatives to traditional fuels, renewable diesel and SAF production have taken center stage. By 2030, vegetable oils are projected to account for over 40% of...

Indivior Announces Q3 2023 Financial Results

Webcast link: https://edge.media-server.com/mmc/p/stcq4w5cParticipants may access the presentation telephonically by registering with the following link: https://register.vevent.com/register/BIf8e71289ddc241b399540e669d753461 Webcast link:https://edge.media-server.com/mmc/p/stcq4w5cParticipants may access the presentation telephonically by registering with the following link:https://register.vevent.com/register/BIf8e71289ddc241b399540e669d753461 (Please note this is a change from...

Eccogene Enters Exclusive License Agreement With AstraZeneca to Develop and…

BOSTON and SHANGHAI, Nov. 9, 2023 /PRNewswire/ -- Eccogene announced today that it entered into an exclusive license agreement with AstraZeneca under which AstraZeneca will develop and commercialize Eccogene's small molecule GLP-1 receptor agonist (GLP-1RA) ECC5004 for the potential treatment of obesity, type-2 diabetes and other comorbidities. BOSTONandSHANGHAI,Nov. 9, 2023/PRNewswire/ -- Eccogene announced today that it entered into an exclusive license agreement with AstraZeneca...

Mendus AB Interim Report January – September 2023

Press Release Stockholm, Sweden, November 9, 2023So far in 2023, Mendus has realized significant progress in its corporate development, and we aim to end the year strong The progress made in the previous quarters provided the basis for a financing round which we completed in July, to support the next stage of our corporate development. The directed placement and rights issue totaling SEK 317M supports further read-outs of the ongoing ADVANCE II and ALISON vididencel trials, the...

Coloplast Finance B.V. - Announcement no. 05/2023 - Annual Report 2022/23

Hereby please find the Annual Report 2022/23 for the group of Coloplast A/S. Attachment Annual Report 2022-23

Coloplast announces new manufacturing site in Portugal

Coloplast, a leading company within intimate healthcare, will invest around 100 million euros in a new manufacturing site in Portugal to support the company's continued growth. The new manufacturing site will produce Coloplast's intermittent catheters used by people suffering from urinary retention, such as people with spinal cord injury or spina bifida, who are unable to empty their bladder. With the new site, Coloplast aims to meet the increasing global demand for intermittent catheters,...

Coloplast A/S - Annual Report 2022/23 & Remuneration Report 2022/23

FY 2022/23 organic growth of 8% and 28% EBIT margin 1). Reported revenue in DKK grew 9% to DKK 24,500 millionOrganic growth rates by business area: Ostomy Care 8%, Continence Care 7%, Voice and Respiratory Care 10% (8 months), Advanced Wound Care 7% (Advanced Wound Dressings 6%), and Interventional Urology 10%.EBIT 1) was DKK 6,845 million, down 1% from last year. The EBIT margin 1,2) was 28% against 31% last year, reflecting inflationary headwind on input costs and an increase in...

Coloplast A/S - Full-Year Financial Results 2022/23

Announcement of Full-year Financial Results 2022/23(1 October 2022 - 30 September 2023) Coloplast delivered Q4 organic growth of 8% and 28% EBIT margin 1). Reported revenue in DKK grew 3% to 6,226 million, impacted by unfavourable development in currenciesOrganic growth rates by business area: Ostomy Care 9%, Continence Care 6%, Voice and Respiratory Care 13%, Advanced Wound Care 8% (Advanced Wound Dressings 12%), and Interventional Urology 5%.Continued good momentum across...

Coloplast A/S - FY 2023/24 Financial Guidance

Coloplast announces financial guidance for the 2023/24 financial year. Organic revenue growth is expected around 8% and the EBIT margin is expected at 27-28%. The assumptions on the financial guidance are laid out below. Organic growthis expected around 8% in constant currencies. The guidance assumes growth across business areas and regions to be largely in line with the Strive25 ambitions, except for China. Chronic Care: Improvement in growth in China, however, China is not expected...

Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates

Product sales of €106.1 million, an increase of 42.6% compared to the first nine months of 2022IXIARO ®and DUKORAL ®sales benefited from a continued recovery of the travel industryTotal revenues of €111.8 million in the first nine months of 2023Cash position of €171.3 million as of September 30, 2023Includes $50 million of the $100 million available following upsize of credit facility with leading U.S. Healthcare Funds Deerfield and OrbiMed in August 2023 1 Includes a...

Zealand Pharma Announces Financial Results for the First Nine Months of 2023

Company announcement - No. 38 / 2023 Zealand Pharma Announces Financial Results for the First Nine Months of 2023Strong progress across obesity pipeline, first PDUFA date for dasiglucagon in CHI in 2023 and solid financial positionBoehringer Ingelheim advances GCGR/GLP-1R dual agonist survodutide (BI456906) into Phase 3 trials in obesityZealand presents amylin analog ZP8396 6-week trial results at ObesityWeek and initiates GLP-1R/GLP-2R dual agonist dapiglutide 13-week dose...

Roche's Elecsys NfL test, an important aid for those living with Multiple…

Roche Elecsys NfL aids in detection of disease activity in adults with Multiple Sclerosis supporting better disease management decisionsElecsys NfL offers a minimally invasive testing option that can provide rapid answers to patients and caregiversNfL has the potential to provide patient insights for other neurological conditions such as Alzheimer's and Huntington's diseasesBasel, 9 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys®...

NIPPON EXPRESS HOLDINGS Completes Acquisition of Shares in Tramo SA, Making It…

From left to right: Arnaldo Vivoli/Tramo Group CEO, Giovanni Di Maggio/Tramo Group General Director, Shinichi Kakiyama/Executive Officer, Regional General Manager Europe of NXhttps://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202311022196/_prw_PI2fl_Tu0UtVr2.jpg From left to right:Arnaldo Vivoli /Tramo Group CEO,Giovanni Di Maggio /Tramo Group General Director, Shinichi Kakiyama/Executive Officer, Regional General Manager Europe of NX ...

European Wellness and DXN Sign MoU to Establish World-Class Wellness Centre!

Together, they are in pole position to revolutionise the health and wellness industry. Together, they are in pole position to revolutionise the health and wellness industry. "This collaboration is significant; we are moving forward together to capture a new benchmark in holistic wellness solution and rejuvenation management," expressed Prof. Dato' Sri Dr.Mike Chan, who is Chairman, Founder, and Chief Scientist of EW Group. Dr. Mike, who also serves as a Senator of BWA (German…

Herpes Zoster Market Size and Share to Grow Positively by 2032, Assesses…

Key Takeaways from the Herpes Zoster Market Report Key Takeaways from the Herpes Zoster Market Report Discover which therapies are expected to grab the major herpes zoster market share @Herpes Zoster Market Report Herpes Zoster Overview Herpes zoster, commonly known as shingles, is a neurocutaneous condition primarily triggered by the reactivation of the varicella-zoster virus (VZV). This reactivation typically arises from a latent VZV infection in the dorsal sensory or...

Altri Comunicati